Pharmacokinetics and Pharmacodynamics of Tebipenem (SPR859) for Multidrug Resistant Enterobacteriaceae in a Hollow Fibre Infection Model Posted on April 24, 2018 at 2:51 pm.Written by Spero Therapeutics View Presentation Post navigation Antimicrobial activity of Ceftazidime and Piperacillin-Tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary-tract infectionsPharmacokinetics and Pharmacodynamics of SPR994 for Multidrug Resistant Enterobacteriaceae
